Neumora Therapeutics (NMRA) Competitors $1.10 +0.01 (+0.92%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.10 +0.00 (+0.45%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. ABCL, CMRX, PRAX, BCAX, LENZ, CRON, PRTA, AVBP, ORGO, and CVACShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include AbCellera Biologics (ABCL), Chimerix (CMRX), Praxis Precision Medicines (PRAX), Bicara Therapeutics (BCAX), LENZ Therapeutics (LENZ), Cronos Group (CRON), Prothena (PRTA), ArriVent BioPharma (AVBP), Organogenesis (ORGO), and CureVac (CVAC). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. AbCellera Biologics Chimerix Praxis Precision Medicines Bicara Therapeutics LENZ Therapeutics Cronos Group Prothena ArriVent BioPharma Organogenesis CureVac AbCellera Biologics (NASDAQ:ABCL) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Which has more risk & volatility, ABCL or NMRA? AbCellera Biologics has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Do analysts prefer ABCL or NMRA? AbCellera Biologics currently has a consensus target price of $7.00, suggesting a potential upside of 196.61%. Neumora Therapeutics has a consensus target price of $10.14, suggesting a potential upside of 822.08%. Given Neumora Therapeutics' higher possible upside, analysts clearly believe Neumora Therapeutics is more favorable than AbCellera Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Neumora Therapeutics 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Does the media favor ABCL or NMRA? In the previous week, Neumora Therapeutics had 25 more articles in the media than AbCellera Biologics. MarketBeat recorded 29 mentions for Neumora Therapeutics and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.02 beat Neumora Therapeutics' score of 0.08 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, ABCL or NMRA? AbCellera Biologics has higher revenue and earnings than Neumora Therapeutics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbCellera Biologics$28.83M24.39-$146.40M-$0.55-4.29Neumora TherapeuticsN/AN/A-$235.93M-$1.53-0.72 Do insiders & institutionals have more ownership in ABCL or NMRA? 61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 28.0% of AbCellera Biologics shares are owned by insiders. Comparatively, 26.4% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ABCL or NMRA more profitable? Neumora Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -533.32%. AbCellera Biologics' return on equity of -15.73% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AbCellera Biologics-533.32% -15.73% -12.22% Neumora Therapeutics N/A -73.63%-68.97% Does the MarketBeat Community believe in ABCL or NMRA? AbCellera Biologics received 27 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Neumora Therapeutics an outperform vote while only 75.34% of users gave AbCellera Biologics an outperform vote. CompanyUnderperformOutperformAbCellera BiologicsOutperform Votes5575.34% Underperform Votes1824.66% Neumora TherapeuticsOutperform Votes2877.78% Underperform Votes822.22% SummaryAbCellera Biologics beats Neumora Therapeutics on 10 of the 17 factors compared between the two stocks. Remove Ads Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$178.18M$3.04B$5.64B$8.06BDividend YieldN/A1.54%4.57%4.01%P/E Ratio-0.5929.2923.1319.03Price / SalesN/A436.17383.8993.17Price / CashN/A168.6838.1634.64Price / Book0.363.956.944.33Net Income-$235.93M-$71.95M$3.20B$247.06M7 Day Performance-2.65%-3.76%-2.33%-0.37%1 Month Performance-29.49%-10.33%2.84%-3.85%1 Year Performance-92.00%-27.15%10.74%1.27% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics3.2438 of 5 stars$1.10+0.9%$10.14+822.1%-91.3%$178.18MN/A-0.59108ABCLAbCellera Biologics2.4747 of 5 stars$2.59+6.1%$7.00+170.3%-47.4%$771.79M$28.83M-4.25500Positive NewsCMRXChimerix3.5537 of 5 stars$8.50flat$8.53+0.4%+741.6%$764.46M$159,000.00-9.0490Earnings ReportShort Interest ↓PRAXPraxis Precision Medicines2.5431 of 5 stars$37.71+1.6%$123.80+228.3%-34.4%$760.35M$8.55M-3.66110Positive NewsBCAXBicara TherapeuticsN/A$13.80+4.2%$36.50+164.5%N/A$750.94MN/A0.0032Earnings ReportUpcoming EarningsAnalyst ForecastNews CoverageLENZLENZ Therapeutics1.7628 of 5 stars$26.66+0.6%$41.67+56.3%+21.6%$733.18MN/A-5.59110CRONCronos Group1.9068 of 5 stars$1.88+5.0%$3.00+59.6%-32.2%$719.16M$117.62M-14.46450PRTAProthena3.3429 of 5 stars$13.34+2.9%$55.00+312.3%-48.3%$718.05M$135.16M-5.80130Analyst RevisionNews CoveragePositive NewsAVBPArriVent BioPharma1.4346 of 5 stars$20.21+3.5%$39.00+93.0%+3.2%$687.46MN/A-7.8640ORGOOrganogenesis3.5813 of 5 stars$5.42+11.1%$5.50+1.5%+69.2%$687.41M$482.04M-90.33950CVACCureVac3.9857 of 5 stars$3.00+3.8%$10.00+233.3%-8.2%$671.64M$543.28M5.45880News Coverage Remove Ads Related Companies and Tools Related Companies AbCellera Biologics Competitors Chimerix Competitors Praxis Precision Medicines Competitors Bicara Therapeutics Competitors LENZ Therapeutics Competitors Cronos Group Competitors Prothena Competitors ArriVent BioPharma Competitors Organogenesis Competitors CureVac Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
